LASSO-Based Machine Learning Algorithm for Prediction of Lymph Node Metastasis in T1 Colorectal Cancer

Jeonghyun Kang1, Yoon Jung Choi2, Im-kyung Kim3, Hye Sun Lee1, Hogeun Kim1, Seung Hyuk Baik1, Nam Kyu Kim2, Kang Young Lee4

1Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, 2Department of Pathology, Yongin Severance Hospital, Yonsei University College of Medicine, Seoul, 3Department of Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, 4Biostatistics Collaboration Unit, Yonsei University College of Medicine, Seoul, 5Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

Purpose The role of tumor-infiltrating lymphocytes (TILs) in predicting lymph node metastasis (LNM) in patients with T1 colorectal cancer (CRC) remains unclear. Furthermore, clinical utility of a machine learning–based approach has not been widely studied.

Materials and Methods Immunohistochemistry for TILs against CD3, CD8, and forkhead box P3 in both center and invasive margin of the tumor were performed using surgically resected T1 CRC slides. Three hundred and sixteen patients were enrolled and categorized into training (n=221) and validation (n=95) sets via random sampling. Using clinicopathologic variables including TILs, the least absolute shrinkage and selection operator (LASSO) regression model was applied for variable selection and predictive signature building in the training set. The predictive accuracy of our model and the Japanese criteria were compared using area under the receiver operating characteristic (AUROC), net reclassification improvement (NRI)/integrated discrimination improvement (IDI), and decision curve analysis (DCA) in the validation set.

Results LNM was detected in 29 (13.1%) and 12 (12.6%) patients in training and validation sets, respectively. Nine variables were selected and used to generate the LASSO model. Its performance was similar in training and validation sets (AUROC, 0.795 vs. 0.765; p=0.747). In the validation set, the LASSO model showed better outcomes in predicting LNM than Japanese criteria, as measured by AUROC (0.765 vs. 0.518, p=0.003) and NRI (0.447, p=0.039)/IDI (0.121, p=0.034). DCA showed positive net benefits in using our model.

Conclusion Our LASSO model incorporating histopathologic parameters and TILs showed superior performance compared to conventional Japanese criteria in predicting LNM in patients with T1 CRC.

Key words Tumor-infiltrating lymphocytes, Lymph node, T1 colorectal cancer, Machine learning, LASSO

Introduction

Colorectal cancers (CRCs) confined to the submucosa (pT1) are found in approximately 5%-13% of overall CRC patients. [1,2] Although curative resection anticipates good clinical outcomes in T1 CRC, non-surgical treatment is of interest due to reduced additional burden. Accurate prediction of lymph node metastasis (LNM) after endoscopic resection or local excision is essential for deciding if additional curative resection is needed. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines (“Japanese criteria”) recommends an additional surgical resection if one or more of the following is applicable: (1) positive vertical resection margin; (2) depth of submucosa invasion ≥ 1,000 μm; (3) lymphovascular invasion (LVI) positive; (4) poorly differentiated adenocarcinoma, signet ring cell carcinoma, or mucinous carcinoma; or (5) grade 2/3 budding at the site of deepest invasion [3]. This criterion is based mainly on pathologic features of the obtained specimens. In fact, most of the patients who underwent such additional surgeries harbor no metastatic lymph nodes [4-6], resulting in overtreatment. The probability of LNM is known to increase with more risk factors [7], but these additional risks do not seem to be taken into account because the current guidelines only make all-or-nothing decisions based on each included variable. Given the lack of a reliable tool that can predict LNM, additional biomarkers have been investigated to raise the predictability using different approaches [8,9].

Tumor-infiltrating lymphocytes (TILs) mediate local host anti-tumor immunity of human malignancies and are known to be important prognostic factors in various cancers [10,11]. TILs are composed of various regulatory subtypes. CD8+ T lymphocytes are critical effectors of anti-tumor immunity and CD4+ T lymphocytes help induce, maintain, and remember CD8+ T cells [12]. A subset of T cells, called regulatory...
T lymphocytes, inhibit anti-tumor immune reaction and are considered a key factor in immune escape in cancer patients. The transcription factor forkhead box P3 (FOXP3) functions as a master regulator of the development and function of regulatory T cells and is an important developmental factor for CD4+CD25+ T regulatory cells that distinguishes "regulatory cells" from conventional "helper cells" among the CD4+ helper T cells [13,14]. Previous studies have demonstrated that immunoscores (defined as summation of specific number imposed according to the densities of CD3+ or CD8+ positive cells in tumor center [TC] and invasive margin [IM]) are better at estimating patient’s prognosis compared to the TNM stage system in colon and rectal cancers, respectively [15]. Nevertheless, the respective prognostic role of spatial distribution of CD3+ and CD8+ in stage II and stage III CRC showed different results [16,17]. Moreover, the role of TILs in predicting LNM in T1 CRC has not been investigated sufficiently.

Machine learning–based algorithms have been widely used in clinical decision making [18]. Of them, the least absolute shrinkage and selection operator (LASSO) is one of the most commonly used algorithms and its clinical efficacy has been demonstrated previously [17,19]. Such situations could yield many insights for the adoption of machine learning algorithms in predicting LNM in T1 CRC.

The aim of the present study was to investigate the predictive value of immunohistochemistry (IHC) results of TILs in addition to routinely reported pathologic parameters. In addition, we hypothesized that a machine learning–based algorithm that incorporated TILs and conventional histopathologic parameters could be used to improve the predictive accuracy of detecting LNM in T1 CRC patients undergoing curative resection.

Materials and Methods

1. Patients and samples

Patients were identified from a prospectively collected database of CRC resections in a tertiary referral center. This retrospective, single center based study initially considered a total of 381 patients who had undergone potentially curative resection of pathologic T1 CRC between April 2004 and December 2011. In case of CRCs treated with endoscopic procedures such as endoscopic mucosal resection or endoscopic submucosal dissection, surgeons usually recommended additional curative surgical resection with lymph node dissection to the patients when invasion to submucosa or deeper was suspected, resection margin was either vertical or lateral involvement was detected, LVI was noted, or poorly differentiated or mucinous/signet ring cell carcinoma were suspected, resection margin was either vertical or lateral involvement was detected, LVI was noted, or poorly differentiated or mucinous/signet ring cell carcinoma were reported. In this study, we included surgically resected specimens only, which allowed us to evaluate the correct pathologic LNM status.

The inclusion criteria for this study was the availability of formalin-fixed, paraffin-embedded tissue. Exclusion criteria were as follows: those who underwent neoadjuvant therapy, such as preoperative chemoradiotherapy for rectal cancer or neoadjuvant chemotherapy for colon cancer; those who underwent emergency operations; those who had a history of hereditary nonpolyposis CRC, ulcerative colitis or Crohn’s disease; those who was diagnosed as stage IV; and patients with missing data i.e., total retrieved lymph node numbers.

Finally, 316 patients met the inclusion criteria and constitute the study cohort. This study conforms to the TRIPOD (Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis) statement for studies developing a prediction model.

2. Pathologic evaluation

For this retrospective study, the examinations of pathologic features, including depth of gross morphology, histologic grade, depth of submucosa invasion, LVI, tumor budding, presence of background adenoma (BGA), and immunochemical examinations were conducted by a single experienced pathologist (Y.J.C.) who did not know the patient’s clinical outcomes or LNM status.

Level 2 of Haggitt’s classification for pedunculated type and muscularis mucosa in other non-pedunculated type, such as sessile and superficial cancers, were used as baseline. The vertical distance from baseline to the deepest invasive lesion was used as the depth of invasion in our study [4]. Tumors were classified histologically as: well, moderately, and poorly differentiated adenocarcinomas or as mucinous or signet ring cell type, based on the most predominant histologic feature [8]. Tumor budding is a cancer cell cluster composed of fewer than five cancer or undifferentiated cells, isolated from large cancer portions without forming a unique structure [20]. After selecting the area where budding foci was most intense, the number of budding foci were counted using a magnification of ×200 in hematoxylin and eosin stained (H&E) slides. Tumor budding was defined as high in case of presence of more than five tumor budding, otherwise it was defined as low [21]. LVI was evaluated using H&E slides.

3. IHC and evaluation of IHC results using image analysis software

Representative sections of primary tumors were processed for additional immunohistochemical staining with antibodies against mismatch repair (MMR) status (MLH1 [1:400, clone ES05, Leica Biosystems, Newcastle upon Tyne, UK] and MSH2 [1:800, clone G219-1129, Cell Marque, Rock-
lin, CA) and TILs such as CD3 (1:200, clone F7.2.38, Dako, Glostrup, Denmark), CD8 (1:100, clone C8/144B, Dako), and FOXP3 (1:150, clone 236A/E7, Abcam, Cambridge, UK) using a BOND-MAX automatic stainer (Leica Biosystems, Melbourne, Australia) with Bond Polymer Refine Detection (Leica Biosystems, Newcastle upon Tyne, UK) kit.

To evaluate the MMR status, adjacent normal colon tissue served as an internal control for positive staining and a negative control staining was carried out without the primary antibody. Expression was reported as either MMR proficient (tumor cell nuclear expression with positive immune cell expression) or MMR deficient (tumor nuclear expression absent with normal immune cell expression).

An automated imaging software program (Image Pro Plus ver. 7.0, Media Cybernetics, Rockville, MD) was used to evaluate the percentage of each TILs subtype among the detected cells. The density of TILs was expressed by measuring the area occupied by mononuclear cells over the stromal area captured by NIS-Element F (ver. 4.30, Nikon, Tokyo, Japan) under ×400 magnification. Immunoreactivity was measured at two points: in the center of the tumor (TC) and in the IM (S1 Fig.). Spatial location of TC and IM was selected by the pathologist. The mean percentage of the three areas occupied by TILs in TC and IM per section was reported as the density of TILs.

4. Development of LASSO-derived prediction model in the training set

A total of 316 patients were allocated to the training and validation sets using computer-generated random sampling at a fixed ratio; 70% of the patients were assigned to the training set and the remaining 30% were assigned to the validation set.

Using clinicopathologic variables, including TILs information dichotomized into high and low subgroups according to the spatial distributions, LASSO regression was used to generate the predictive model in the training set. LASSO regression is known to be able to remove unimportant variables via the regression coefficients penalizing the size of the parameters. Applying the LASSO regression method, feature selection and predictive signature building was done. LASSO regression shrinks the coefficient estimates toward zero, with the degree of shrinkage dependent on an additional parameter, $\lambda$. To determine the optimal values for $\lambda$, a 10-time cross-validation was used, and we chose $\lambda$ via the minimum criteria. The LASSO model was designed to predict the presence of LNM in patients with T1 CRC and is the linear predictor of the binary model built on the training set with selected variables via LASSO algorithm.

5. Validation of LASSO model using area under the receiver operating characteristic, net reclassification improvement, integrated discrimination improvement, and decision curve analysis in the validation set

The performance of the LASSO model, in comparison to Japanese criteria, was measured via area under the receiver operating characteristic (AUROC) analysis, net reclassification improvement (NRI), integrated discrimination improvement (IDI) calculation, and decision curve analysis (DCA) in the validation set. NRI quantifies the net proportion of patients with and without event of interest who are reclassified as higher and lower risk, respectively.

6. Statistical analysis

The clinicopathologic characteristics were analyzed using a variance test where appropriate. The chi-square test or Fisher exact test was used for comparison of categorical variables. Continuous variables were analyzed via Student t test or Mann-Whitney U test. The cutoff values for all immunohistochemical markers were determined at the maximum of Youden’s index and the maximum of accuracy. A univariable analysis was performed to calculate the odds ratio of the single variables in the logistic regression (LR) model after entering one of the variables under investigation. Univariable analysis denoted the association between LNM and the parameter through a 1:1 matching.

A two-sided $p$-value less than 0.05 was considered statistically significant. All statistical analyses were performed using SPSS software ver. 23.0 (IBM Corp., Armonk, NY) and R ver. 3.5.1 (R-project, Institute for Statistics and Mathematics, Vienna, Austria).

Results

1. Patient characteristics

Three hundred and sixteen patients were included in our analysis. Our initial cohort was categorized into 221 patients in the training set and the remaining 95 patients in the validation set. LNM was detected in 29 (13.1%) and 12 (12.6%) patients after a curative resection in the training and validation set. NRI quantifies the net proportion of patients with and without event of interest who are reclassified as higher and lower risk, respectively.
2. Distribution of TILs and defining cut-off value of TILs in the training set

Distribution of TILs according to LNM based on the anatomical location are illustrated in S2 Fig. We found no significant difference in the mean numbers between the LNM status. Receiver operating characteristic curve analysis to predict LNM based on each TILs subtype’s densities and AUROC values are shown in S3 Fig. and S4 Table. Area under the curve (AUC) values are 0.55, 0.50, 0.50, 0.59, 0.52, and 0.53 in CD3_invasive margin (CD3_IM), CD3_tumor center (CD3_TC), CD8_invasive margin (CD8_IM), CD8_tumor center (CD8_TC), FOXP3_invasive margin (FOXP3_IM), and FOXP3_tumor center (FOXP3_TC), respectively. We calculated the cut-off value of each TILs subtype using

---

Table 1. Comparison of clinicopathological characteristics between the training and validation set

|                        | Training set (n=221) | Validation set (n=95) | p-value |
|------------------------|----------------------|-----------------------|---------|
| **Sex**                |                      |                       |         |
| Male                   | 123 (55.7)           | 59 (62.1)             | 0.347   |
| Female                 | 98 (44.3)            | 36 (37.9)             |         |
| **Age (yr)**           |                      |                       |         |
| < 70                   | 177 (80.1)           | 77 (81.1)             | 0.966   |
| ≥ 70                   | 44 (19.9)            | 18 (18.9)             |         |
| **Preoperative CEA (ng/mL)** |          |                       |         |
| < 5.0                  | 208 (94.1)           | 73 (76.8)             | < 0.001 |
| ≥ 5.0                  | 13 (5.9)             | 22 (23.2)             |         |
| **Tumor location**     |                      |                       |         |
| Colon                  | 129 (58.4)           | 60 (63.2)             | 0.502   |
| Rectum                 | 92 (41.6)            | 35 (36.8)             |         |
| **Retrieved lymph node numbers** | 12 (7-17)   | 14 (12-21)            | < 0.001 |
| **Depth of invasion (μm)** |                    |                       |         |
| < 1,000                | 20 (9.0)             | 6 (6.3)               | 0.557   |
| ≥ 1,000                | 201 (91.0)           | 89 (93.7)             |         |
| **Histologic grade**   |                      |                       |         |
| G1                     | 93 (42.1)            | 28 (29.5)             | 0.047   |
| G2, G3, etc.           | 128 (57.9)           | 67 (70.5)             |         |
| **LVI**                |                      |                       |         |
| Present                | 27 (12.2)            | 14 (14.7)             | 0.668   |
| Absent                 | 194 (87.8)           | 81 (85.3)             |         |
| **Gross morphology**   |                      |                       |         |
| Pedunculated           | 17 (7.7)             | 16 (16.8)             | 0.025   |
| Flat and sessile       | 204 (92.3)           | 79 (83.2)             |         |
| **Tumor budding**      |                      |                       |         |
| Low grade              | 88 (39.8)            | 38 (40.0)             | > 0.99  |
| High grade             | 133 (60.2)           | 57 (60.0)             |         |
| **Background adenoma** |                      |                       |         |
| Present                | 196 (88.7)           | 84 (88.4)             | > 0.99  |
| Absent                 | 25 (11.3)            | 11 (11.6)             |         |
| **LNM**                |                      |                       |         |
| Negative               | 192 (86.9)           | 83 (87.4)             | > 0.99  |
| Positive               | 29 (13.1)            | 12 (12.6)             |         |
| **MMR**                |                      |                       |         |
| MMR-deficient          | 14 (6.3)             | 8 (8.4)               | 0.669   |
| MMR-proficient         | 207 (93.7)           | 87 (91.6)             |         |

Values are presented as number (%) or median (IQR). CEA, carcinoembryonic antigen; IQR, interquartile range; LNM, lymph node metastasis; LVI, lymphovascular invasion; MMR: mismatch repair. *Histologic grade: G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated. †Tumor budding grade was as follows: grade 1, 0-4/grade 2, 5-9/grade 3, 10 or more. Grade 1 was defined as low grade and grade 2/3 as high grade.
Table 2. Univariable analysis for predicting lymph node metastasis in the training set (n=221)

|                          | LN positive, n (%) | Univariable analysis |
|--------------------------|--------------------|----------------------|
|                          | OR (95% CI)       | p-value              |
| Sex                      |                   |                      |
| Female                   | 14/98 (14.3)      | Reference            |
| Male                     | 15/123 (12.2)     | 0.833 (0.37-1.83)    | 0.647   |
| Age (yr)                 |                   |                      |
| < 70                     | 24/177 (13.6)     | Reference            |
| ≥ 70                     | 5/33 (15.4)       | 0.817 (0.26-2.12)    | 0.699   |
| Preoperative CEA (ng/mL) |                   |                      |
| < 5.0                    | 27/208 (13.0)     | Reference            |
| ≥ 5.0                    | 2/13 (15.4)       | 1.218 (0.18-4.86)    | 0.803   |
| Tumor location           |                   |                      |
| Colon                    | 14/129 (10.9)     | Reference            |
| Rectum                   | 15/92 (16.3)      | 1.6 (0.72-3.53)      | 0.239   |
| Depth of invasion (μm)   |                   |                      |
| < 1,000                  | 3/20 (15.0)       | Reference            |
| ≥ 1,000                  | 26/201 (12.9)     | 0.841 (0.25-3.78)    | 0.794   |
| Histologic gradea        |                   |                      |
| G1                       | 7/93 (7.5)        | Reference            |
| G2, G3, etc.             | 22/128 (17.2)     | 2.549 (1.08-6.70)    | 0.040   |
| LVI                      |                   |                      |
| Absent                   | 20/194 (10.3)     | Reference            |
| Present                  | 9/27 (33.3)       | 4.35 (1.67-10.84)    | 0.001   |
| Gross morphology         |                   |                      |
| Pedunculated             | 2/17 (11.8)       | Reference            |
| Flat and sessile         | 27/204 (13.2)     | 1.144 (0.29-7.51)    | 0.863   |
| Tumor buddingb           |                   |                      |
| Low grade                | 10/133 (7.5)      | Reference            |
| High grade               | 19/88 (21.6)      | 3.387 (1.52-7.97)    | 0.003   |
| Background adenoma       |                   |                      |
| Present                  | 22/196 (11.2)     | Reference            |
| Absent                   | 7/25 (20.0)       | 3.075 (1.09-7.96)    | 0.024   |
| MMR                      |                   |                      |
| MMR-deficient            | 1/14 (7.1)        | Reference            |
| MMR-proficient           | 28/207 (13.5)     | 2.033 (0.38-37.65)   | 0.502   |
| CD3_IM                   |                   |                      |
| Low (< 11.3)             | 10/55 (18.2)      | Reference            |
| High (≥ 11.3)            | 19/166 (11.4)     | 0.581 (0.25-1.38)    | 0.203   |
| CD3_TC                   |                   |                      |
| Low (< 9.2)              | 2/39 (5.1)        | Reference            |
| High (≥ 9.2)             | 27/182 (14.8)     | 3.222 (0.90-20.53)   | 0.121   |
| CD8_IM                   |                   |                      |
| Low (< 28.2)             | 29/199 (14.6)     | Reference            |
| High (≥ 28.2)            | 0/27 (0)          | 0 (NA-1.68e+26)      | 0.990   |
| CD8_TC                   |                   |                      |
| Low (< 18.5)             | 24/133 (18.0)     | Reference            |
| High (≥ 18.5)            | 5/88 (5.7)        | 0.273 (0.08-0.69)    | 0.011   |
| FOXP3_IM                 |                   |                      |
| Low (< 15.1)             | 16/99 (16.2)      | Reference            |
| High (≥ 15.1)            | 13/122 (10.7)     | 0.618 (0.27-1.35)    | 0.230   |

(Continued to the next page)
Youden’s index to be 11.3, 9.2, 28.2, 18.5, 15.1, and 20.3 in CD3_IM, CD3_TC, CD8_IM, CD8_TC, FOXP3_IM, and FOXP3_TC, respectively (S4 Table). Each TILs subtype was categorized as high or low according to these cutoff values.

3. Univariable analysis using clinicopathologic parameters and TILs for predicting LNM in the training set

There was no difference in incidence of LNM due to sex, age, CEA level, tumor location, depth of invasion, and gross morphology (pedunculated versus others). Mean depth of invasion did not differ according to LNM (2,947 μm in lymph node [LN]–positive group vs. 2,550 μm in LN-negative group, p=0.099). Among clinicopathologic parameters, histologic grade (grade 1 vs. grade 2, grade 3 and etc., p=0.040), LVI (positive vs. negative, p=0.001), tumor budding (presence vs. absence, p=0.003), and BGA (absence vs. presence, p=0.024) were associated with LNM in the training set. With respect to TILs, CD8 densities in TC dichotomized as 18.5 were identified as a significant parameter for predicting LNM in the training set (p=0.011) (Table 2).

4. Generating LASSO model to predict LNM in the training set

The binomial deviance curve was plotted versus log (λ), where λ is the tuning parameter (A). LASSO coefficient profiles of clinicopathologic variables (B). LASSO, least absolute shrinkage and selection operator.

---

Table 2. Continued

| FOXP3_TC   | LN positive, n (%) | Univariable analysis OR (95% CI) p-value |
|------------|--------------------|----------------------------------------|
| Low (< 20.3) | 23/157 (14.6)     | Reference                               |
| High (≥ 20.3) | 6/64 (9.4)        | 0.602 (0.21-1.47) 0.290                |

CEA, carcinoembryonic antigen; CI, confidence interval; IM, invasive margin; LN, lymph node; LVI, lymphovascular invasion; MMR, mismatch repair; NA, not available; OR, odds ratio; TC, tumor center. aHistologic grade: G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated. bTumor budding grade was as follows: grade 1, 0-4/grade 2, 5-9/grade 3, 10 or more. Grade 1 was defined as low grade and grade 2/3 as high grade.
The linear predictor was defined as 
\[-2.51312270 + \text{histology grade (grade 1 vs. others)} \times 0.28665580 + \text{LVI (absence vs. presence)} \times 0.84002838 + \text{tumor budding (absence vs. presence)} \times 0.60610111 + \text{BGA (presence vs. absence)} \times 0.33894896 + \text{CD3_IM (high vs. low)} \times -0.07225639 + \text{CD3_TC (high vs. low)} \times 0.34769731 + \text{CD8.IM (high vs. low)} \times -0.35012378 + \text{CD8_TC (high vs. low)} \times -0.66414982 + \text{FOXP3_TC (high vs. low)} \times -0.03525056.\]

5. Performance of the LASSO model in the validation set

AUROC comparison of the LASSO model in the training and validation sets showed similar results. (AUROC, 0.795 vs. 0.765; p=0.747) (Fig. 2).

In Japanese criteria, patients with either one of the following results were classified as positive:

- Histology grade (grade 1 vs. others)
- LVI (absence vs. presence)
- Tumor budding (absence vs. presence)
- BGA (presence vs. absence)
- CD3.IM (high vs. low)
- CD3_TC (high vs. low)
- CD8.IM (high vs. low)
- CD8_TC (high vs. low)
- FOXP3_TC (high vs. low)

Table 3. NRI and IDI in the training set and the validation set

| Training set (n=221) | Validation set (n=95) |
|----------------------|-----------------------|
| **Japanese criteria vs. LASSO model** | **Japanese criteria vs. LASSO model** |
| NRI (95% CI) \(a\) | 0.722 (0.402-1.041) | < 0.001 | 0.447 (0.041-0.854) | 0.039 |
| IDI (95% CI) | 0.187 (0.100-0.274) | < 0.001 | 0.121 (0.008-0.234) | 0.034 |

\(a\) Cutoff of “0, 0.1, 0.2, 1” was used in this analysis.

Fig. 3. Decision curve analysis of Japanese criteria and LASSO model in the training (A) and validation (B) set. The y-axis measures the net benefit. The green line represents the LASSO model. The red line represents the Japanese criteria. The gray line represents the assumption that all patients underwent surgeries. The black line represents the assumption that patients underwent no surgeries. The net benefit was calculated by subtracting the proportion of all patients who are false positive from the proportion who are true positive, weighting by the relative harm of forgoing treatment compared with the negative consequences of an unnecessary treatment. The decision curve showed that if the threshold probability of a patient or doctor is >10%, using the LASSO model in the current study to predict LNM adds more benefit than the treat-all-patients scheme or the treat-none scheme. For example, if the personal threshold probability of a patient is 20% (i.e., the patient would opt for surgery if his/her probability of LNM was > 20%), then the net benefit is 0.35 when using the LASSO model to make the decision of whether to undergo surgery, with added benefit than the treat-all scheme or the treat-none scheme. This decision curve analysis showed that the net benefit was comparable on the basis of the Japanese criteria and the treat-all or treat-none strategies.
for the surgery group (coded as 1) and other patients were denoted as negative for the surgery group (coded as 0): positive vertical resection margin, depth of submucosal invasion ≥ 1,000 μm, LVI positive, poorly differentiated adenocarcinoma, signet ring cell carcinoma, or mucinous carcinoma or grade 2/3 budding at the site of deepest invasion.

In the validation set, AUROC demonstrated better predictive accuracy of LASSO model compared to Japanese criteria (0.765 in the LASSO model vs. 0.518 in the Japanese criteria, p=0.003) (Fig. 2). In addition, the LASSO model showed significantly improved prediction for LNM compared to Japanese criteria, as measured by NRI (0.447, p=0.039) and IDI (0.121, p=0.034) (Table 3). DCA showed positive net benefit in using LASSO model in the training set and validation set, respectively (Fig. 3). Sensitivity, specificity, positive predictive value, and negative predictive value using the LASSO model at each cut-off point in overall set are illustrated in S5 Table.

6. Clinical significance of immunoscore-like score in predicting LNM in T1 CRC

Immunoscore-like score was calculated based on the recommendation [15]. In our cohort, there was no difference in immunoscore-like score between the LN positive and the negative group (p=0.630) (S6 Fig.).

Discussion

Previous studies investigating predictors of LNM in T1 CRC mainly focused on histopathologic parameters [4,22]. Although we expect the combination of pathologic risk factors could help in discriminating the risk of LNM in most patients with T1 CRC, more than 80% of the patients who were candidates for additional surgery were node-negative in final pathologic examinations. This study demonstrated that a machine learning–based algorithm that incorporated clinicopathologic parameters and TILs showed high predictive accuracy of LNM in T1 CRC and had superior discriminatory performance when compared with the conventional Japanese criteria.

Although prognostic value of the inflammatory cell reaction on survival in CRC has been thoroughly studied, the role of lymphocytic infiltration on LNM in early CRC has not been studied as extensively. A previous study considering peritumoral lymphocytic infiltration (PLI) as one of the candidates to predict LNM did not reveal any difference of PLI rate between the node-positive and node-negative groups. [20] Although statistically insignificant, the rate of PLI was conspicuous—at 8.3% in the node-positive group and 22.6% in the node-negative group (p=0.1). Considering the relatively low number of enrolled patients (n=111), the lack of association might be due to a type-II error [20]. Compared to the H&E slide–based evaluation of PLI in the previous study, we evaluated the role of IHC-stained TILs at different anatomical subsites, such as IM and TC. Univariable analysis demonstrated that lower densities of CD8+ T cells in TC were significantly correlated with higher rate of LNM in T1 CRC. In the equation that formed the linear predictor of LASSO model, the absolute value of CD8_TC (0.66414982) was larger than that of other IHC values. This result indicates that CD8_TC acted as one of the most obvious factors in predicting LNM, which was predictable from the results of univariable analysis.

A recent meta-analysis reported that the clinical significance of various TILs in CRC showed definite differences according to anatomical subsites [23]. High densities of CD3+ T cells indicated poor disease-free survival (DFS) in the invasive margin, whereas high densities of CD8+ T cells were a favorable prognosticator with respect to DFS in tumor center. Furthermore, several studies demonstrated that the significance of specific TILs according to spatial distribution might be different depending on the stage. One study revealed that both CD3+ T cells in both TC and IM are favorable prognosticators in stage III colon cancer, whereas another study observed the same trends only in stage II colon cancer but not in stage III colon cancer [16,17]. As far as we know, the clinical significance of spatial distribution of TILs as a predictor of LNM in T1 CRC has not been investigated sufficiently. When applying LR-based univariable or multivariable analysis, only CD8_TC would be left as an independent factor. In contrast, using LASSO model, we can estimate the relative role of each spatial TILs subtype using the coefficients imposed on respective variables. Along with CD8_TC, CD3_TC, and CD8_IM are thought to have a certain role in predicting LNM, although the direction of CD3_TC and CD8_IM would be different. Considering the different roles of each TILs subtype depending on the anatomical subsites or stages in non-metastatic CRC patients, it appears that our LASSO model is more reflective of the complex interactions of each TILs subtype. Further research is required to confirm our hypothesis.

Several recent studies have introduced machine learning algorithms for predicting LNM in T1 CRC [18,24,25]. It was reported that an artificial intelligence model using support vector machine (SVM) showed better discrimination than the LR-based model (AUC; 0.821 in SVM vs. 0.789 in LR, p=not stated) among 100 validation sets out of 690 T1 CRC patients [18]. The other study developed a random forest classifier–based prediction model using cytokeratin immunostaining images of resected whole slide images and reported similar predictive ability (AUC, p=0.1) and fewer false-negative cas-
es compared to the LR-based clinical model [24]. However, one should bear in mind that the LR-based clinical models that were used to compare with the aforementioned machine learning algorithms (SVM and random forest classifier) were not the same as the Japanese criteria–based decision model.

The risk assessment LR-based model generated in the prior two studies constructed prediction probabilities by combining each conventional histopathologic risk factor, whereas the Japanese criteria classified patients solely into “surgery” or “no surgery” subgroups without considering the imposed risk of each clinicopathologic variable. It is in this context that we developed a LASSO model and compared it with the Japanese criteria used in current clinical practice. The LASSO-based prediction model is a classifier that can accumulate relative risks of meaningful variables and maximize its predictive power. This fundamental characteristic might be one possible reason for the better diagnostic accuracy of the LASSO model. In a similar way, a recent Dutch T1 CRC working group demonstrated that a LASSO-derived prediction model (AUC, 0.83; 95% confidence interval [CI], 0.76 to 0.90) showed better AUC value than the conventional prediction models suggested by American Society for Gastrointestinal Endoscopy / European Society of Gastrointestinal Endoscopy (AUC, 0.67; 95% CI, 0.60 to 0.74; p = 0.002) and JSCCR guidelines (AUC, 0.64; 95% CI, 0.58 to 0.70; p < 0.001), respectively, in 708 T1 pedunculated colorectal carcinoma [25].

Previously, the depth of invasion of T1 CRC was classified as SM1 (submucosa 1), SM2, and SM3, respectively [26]. The rate of LNM according to this definition was reported as 0%-3% in SM1, 8%-10% in SM2, and 23%-25% in SM3 [27,28], and SM3 was regarded as a strong indicator for an additional surgery. To clarify the depth of invasion using SM categories, the whole submucosa layer should be evaluated, which is not always possible after endoscopic treatment. In a large retrospective study, it was recommended that a 1,000 μm depth of invasion could be used as a cut-off value for predicting LNM [4]. In our study, however, there was no difference of LNM rate according to depth of invasion dichotomized as 1,000 μm and, therefore, depth of invasion was not selected as a parameter in the LASSO model. Although it is very difficult to explain why depth of invasion did not predict LNM in our cohort, there are several other studies that also reported no association between depth of invasion with LNM [8,22,29]. Selection bias might be one possible reason for this dissociation [29]. In addition, long-span retrospective studies undergoing histopathologic examinations by various pathologists inevitably showed some heterogeneities of dealing with pathologic slides. In our study, depth of invasion as well as other histopathologic parameters were re-evaluated for this study by one pathologist, which is a merit of this study. Large scale prospective studies are required to reveal the discrepancy of the role of depth of invasion on LNM in T1 CRC.

The main limitation of our study is that it was based on a single center, retrospective data collection. Our hospital is one of the largest referral centers in our nation, which skews cases toward more advanced stage patients. The accuracy of Japanese criteria measured by AUC in this study was around 0.52, which is approximately the same probability as tossing a coin. Such a situation would be very embarrassing given its firm status as a predictive model. Although this might reflect the real situation, some unmeasurable biases, such as inclusion of only patients who underwent surgeries, might have acted in reducing the overall performance. Nevertheless, it is impossible to identify the actual incidence of LNM among those patients who did not undergo surgeries, and such a situation would be the main dilemma in dealing with this issue. Also, IHC on paraffin sections might be semiquantitative although we applied image analyzer–based measurements. Artificial intelligence–guided whole slide image analysis has been actively adopted in medicine [17]. It would be an interesting issue that computer-aided detection could minimize the subjectivity of measuring TILs using pathologic manual estimation or image analyzer–based measurements [30]. Despite the internal validation, a larger prospective external validation is required before the LASSO model can be used as a clinical decision maker. It is expected that endoscopic resection will be performed more frequently as the incidence of early CRC increases. Therefore, it is considered to be very important clinically whether the predictive power can be increased through such TILs measurement and machine learning adoption in the specimen after endoscopic procedure. Our study has a limitation in that it cannot provide a direct answer to such a point because it is not a study using a tissue from endoscopic procedure. However, if the center and IM of the tumor can be identified pathologically even in specimens using endoscopic resection, the model developed by us can be used when the density of each location can be measured after IHC. Additional research is needed to confirm the possibility in practical application.

In conclusion, we developed a LASSO-based prediction model for predicting LNM in patients with T1 CRC, and it outperformed the current Japanese guidelines. This finding suggests that machine learning can potentially improve the accuracy of prediction, thereby minimizing unnecessary surgical resections. As the rate of CRCs detected early is growing, incidence of endoscopic treatments for early stage CRC may also be increasing. Evaluation of TILs after endoscopic treatments and application of a new prediction model might be beneficial in deciding for a subsequent radical surgery in T1 CRC.
Electronic Supplementary Material

Supplementary materials are available at Cancer Research and Treatment website (https://www.e-crt.org).

Ethical Statement

The protocol of the present study was approved by the institutional review board of the Severance Hospital, Yonsei University College of Medicine (Seoul, Republic of Korea) (approval no. 4-2012-0900). Informed consent was waived by the institutional review board due to the retrospective study design.

Author Contributions

Conceived and designed the analysis: Kang J, Choi YJ, Kim IK, Lee KY. Collected the data: Kang J, Choi YJ, Kim H, Baik SH, Kim NK, Lee KY. Contributed data or analysis tools: Kang J, Choi YJ, Kim IK, Lee HS, Lee KY. Performed the analysis: Kang J, Lee KY. Wrote the paper: Kang J, Choi YJ, Lee KY.

Conflicts of Interest

Conflict of interest relevant to this article was not reported.

Acknowledgments

We would like to thank Editage (www.editage.co.kr) for English language editing. This study was supported by a CMB-Yuhan research grant of Yonsei University College of Medicine for (6-2014-0069).

References

1. Dai W, Mo S, Xiang W, Han L, Li Q, Wang R, et al. The critical role of tumor size in predicting prognosis for T1 colon cancer. Oncologist. 2020;25:244-51.
2. Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010;28:264-71.
3. Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajikyo Y, Hamaguchi T, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25:1-42.
4. Kitajima K, Fujimori T, Fujii S, Takeda J, Ohkura Y, Kawamata H, et al. Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative study. J Gastroenterol. 2004;39:534-43.
5. Kobayashi H, Mochizuki H, Morita T, Kotake K, Teramoto T, Kameoka S, et al. Characteristics of recurrence after curative resection for T1 colorectal cancer: Japanese multicenter study. J Gastroenterol. 2011;46:203-11.
6. Oh JR, Park B, Lee S, Han KS, Youk EG, Lee DH, et al. Nomogram development and external validation for predicting the risk of lymph node metastasis in T1 colorectal cancer. Cancer Res Treat. 2019;51:1275-84.
7. Ueno H, Mochizuki H, Hashiguchi Y, Shimazaki H, Aida S, Hase K, et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology. 2004;127:385-94.
8. Nishida T, Egashira Y, Akutagawa H, Fujii M, Uchiyama K, Shibayama Y, et al. Predictors of lymph node metastasis in T1 colorectal carcinoma: an immunophenotypic analysis of 265 patients. Dis Colon Rectum. 2014;57:905-15.
9. Jung CK, Jung SH, Yim SH, Jung JH, Choi HJ, Kang WK, et al. Predictive microRNAs for lymph node metastasis in endoscopically resectable submucosal colorectal cancer. Oncotarget. 2016;7:32902-15.
10. Geng Y, Shao Y, He W, Hu W, Xu Y, Chen J, et al. Prognostic role of tumor-infiltrating lymphocytes in lung cancer: a meta-analysis. Cell Physiol Biochem. 2015;37:1560-71.
11. Cha YJ, Park EJ, Baik SH, Lee KY, Kang J. Clinical significance of tumor-infiltrating lymphocytes and neutrophil-to-lymphocyte ratio in patients with stage III colon cancer who underwent surgery followed by FOLFOX chemotherapy. Sci Rep. 2019;9:11617.
12. Yu P, Fu XY. Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest. 2006;86:231-45.
13. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057-61.
14. deLeeuw RJ, Kost SE, Kakal JA, Nelson BH. The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res. 2012;18:3022-9.
15. Pages F, Mlecnik B, Marliot F, BINDEA G, Ou FS, Bifulco C, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391:2128-39.
16. Cavalleri T, Bianchi P, Basso G, Celesti G, Grizzi F, Bossi P, et al. Combined low densities of FoxP3+ and CD3+ tumor-infiltrating lymphocytes identify stage II colorectal cancer at high risk of progression. Cancer Immunol Res. 2019;7:751-8.
17. Reichling C, Taieb J, Derangere V, Klopfenstein Q, Le Maltier K, Gornet JM, et al. Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study. Gut. 2020;69:681-90.
18. Ichimasa K, Kudo SE, Morii Y, Misawa M, Matsudaira S, Kouyama Y, et al. Artificial intelligence may help in predicting the need for additional surgery after endoscopic resection of T1 colorectal cancer. Endoscopy. 2018;50:230-40.
19. Huang YQ, Liang CH, He L, Tian J, Liang CS, Chen X, et al.
Development and validation of a radiomics nomogram for preoperative prediction of lymph node metastasis in colorectal cancer. J Clin Oncol. 2016;34:2157-64.
20. Akishima-Fukasawa Y, Ishikawa Y, Akasaka Y, Uzuki M, Inomata N, Yokoo T, et al. Histopathological predictors of regional lymph node metastasis at the invasive front in early colorectal cancer. Histopathology. 2011;59:470-81.
21. Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol. 2012;17:1-29.
22. Wada H, Shiozawa M, Katayama K, Okamoto N, Miyagi Y, Rino Y, et al. Systematic review and meta-analysis of histopathological predictive factors for lymph node metastasis in T1 colorectal cancer. J Gastroenterol. 2015;50:727-34.
23. Zhao Y, Ge X, He J, Cheng Y, Wang Z, Wang J, et al. The prognostic value of tumor-infiltrating lymphocytes in colorectal cancer differs by anatomical subsite: a systematic review and meta-analysis. World J Surg Oncol. 2019;17:85.
24. Takamatsu M, Yamamoto N, Kawachi H, Chino A, Saito S, Ueno M, et al. Prediction of early colorectal cancer metastasis by machine learning using digital slide images. Comput Methods Programs Biomed. 2019;178:155-61.
25. Backes Y, Elias SG, Groen JN, Schwartz MP, Wolfhagen FH, Geesing JM, et al. Histologic factors associated with need for surgery in patients with pedunculated T1 colorectal carcinomas. Gastroenterology. 2018;154:1647-59.
26. Kudo S. Endoscopic mucosal resection of flat and depressed types of early colorectal cancer. Endoscopy. 1993;25:455-61.
27. Kikuchi R, Takano M, Takagi K, Fujimoto N, Nozaki R, Fujiyoshi T, et al. Management of early invasive colorectal cancer: risk of recurrence and clinical guidelines. Dis Colon Rectum. 1995;38:1286-95.
28. Nascimbeni R, Burgart LJ, Nivatvongs S, Larson DR. Risk of lymph node metastasis in T1 carcinoma of the colon and rectum. Dis Colon Rectum. 2002;45:200-6.
29. Choi DH, Sohn DK, Chang HJ, Lim SB, Choi HS, Jeong SY. Indications for subsequent surgery after endoscopic resection of submucosally invasive colorectal carcinomas: a prospective cohort study. Dis Colon Rectum. 2009;52:438-45.
30. Klauschen F, Muller KR, Binder A, Bockmayr M, Hagele M, Seegerer P, et al. Scoring of tumor-infiltrating lymphocytes: from visual estimation to machine learning. Semin Cancer Biol. 2018;52:151-7.